Skip to main content
Top
Published in: Internal and Emergency Medicine 7/2021

01-10-2021 | Idiopathic Pulmonary Fibrosis | IM - ORIGINAL

The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities

Authors: Antonella Caminati, Fabiana Madotto, Sara Conti, Giancarlo Cesana, Lorenzo Mantovani, Sergio Harari

Published in: Internal and Emergency Medicine | Issue 7/2021

Login to get access

Abstract

Placebo arms of clinical trials provide an opportunity to investigate the natural history of idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life IPF population. Objective of this article is to evaluate patients’ characteristics of incident IPF cases and their impact on mortality and hospitalizations risk. We conducted a retrospective cohort study using data from administrative databases from 2000 to 2010. Based on different algorithms reported in literature, incident IPF cases were identified. We applied Cox proportional hazards models to assess relationship between patients’ characteristics, mortality and hospitalization. According to three case definitions, we identified 2338, 460 and 1704 incident IPF cases. Mean age at diagnosis was about 72 years, the proportion of male varied between 59 and 62% and patients with at least one chronic disease were between 70 and 74%. Age, male sex and comorbidities were associated to worse outcomes. Congestive heart failure (CHF), diabetes and cancer were conditions associated to mortality, while those associated to hospitalization were CHF and chronic obstructive pulmonary disease. Our data source provided one of the largest samples of unselected patients with a long follow-up period. Using different algorithms proposed and validated in literature, we observed that mortality and hospitalization rate are high in patients with IPF and age, sex and comorbidities significantly affect clinical outcomes. Females show a significant survival advantage over males, even after adjusting for age and comorbidities. Patients with pre-existing diseases, especially those with pulmonary and cardiovascular diseases are at higher risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199–203PubMedCrossRef Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199–203PubMedCrossRef
2.
go back to reference Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213–2217PubMedCrossRef Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213–2217PubMedCrossRef
3.
go back to reference Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19:275–283PubMedCrossRef Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19:275–283PubMedCrossRef
4.
go back to reference Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real life experience. Eur Respir Rev 24:420–427PubMedCrossRef Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real life experience. Eur Respir Rev 24:420–427PubMedCrossRef
5.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al (2011) ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824 Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al (2011) ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824
6.
go back to reference Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK (2007) Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 176(3):277–284PubMedCrossRef Olson AL, Swigris JJ, Lezotte DC, Norris JM, Wilson CG, Brown KK (2007) Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 176(3):277–284PubMedCrossRef
7.
go back to reference Fernández Pérez ER, Daniels CE, Schroeder DR, St SJ, Hartman TE, Bartholmai BJ et al (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137(1):129–137PubMedCrossRef Fernández Pérez ER, Daniels CE, Schroeder DR, St SJ, Hartman TE, Bartholmai BJ et al (2010) Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 137(1):129–137PubMedCrossRef
8.
go back to reference Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E et al (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140(1):221–229PubMedCrossRef Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E et al (2011) Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140(1):221–229PubMedCrossRef
9.
go back to reference Brown AW, Shlobin OA, Weir N, Albano MC, Ahmad S, Smith M et al (2012) Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. Chest 142(4):1005–1010PubMedCrossRef Brown AW, Shlobin OA, Weir N, Albano MC, Ahmad S, Smith M et al (2012) Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis. Chest 142(4):1005–1010PubMedCrossRef
10.
go back to reference Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al (2004) Idiopathic pulmonary fibrosis study group. A placebo-controlled trialof interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2):125–133 Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al (2004) Idiopathic pulmonary fibrosis study group. A placebo-controlled trialof interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2):125–133
11.
go back to reference King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al (2009) INSPIRE Study Group. Effect of interferon gamma-1b on survival inpatients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374 (9685):222–228 King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al (2009) INSPIRE Study Group. Effect of interferon gamma-1b on survival inpatients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374 (9685):222–228
12.
go back to reference King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al (2008) BUILD-1: a randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75–81PubMedCrossRef King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al (2008) BUILD-1: a randomized placebo controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75–81PubMedCrossRef
13.
go back to reference King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F et al (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(1):92–99PubMedCrossRef King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F et al (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(1):92–99PubMedCrossRef
14.
go back to reference Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al (2011) CAPACITY Study Group. Pirfenidonein patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377 (9779):1760–1769 Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al (2011) CAPACITY Study Group. Pirfenidonein patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377 (9779):1760–1769
15.
go back to reference Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al (2013) ARTEMIS-IPF investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158 (9):641–649 Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al (2013) ARTEMIS-IPF investigators. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158 (9):641–649
16.
go back to reference Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr et al (2012) Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185(10):1044–1048PubMedPubMedCentralCrossRef Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr et al (2012) Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185(10):1044–1048PubMedPubMedCentralCrossRef
17.
go back to reference Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al (2012) Idiopathic pulmonary fibrosis clinical research network (IPFnet) A placebo controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88–95PubMedPubMedCentralCrossRef Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al (2012) Idiopathic pulmonary fibrosis clinical research network (IPFnet) A placebo controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88–95PubMedPubMedCentralCrossRef
18.
go back to reference Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ (2012) Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 (21): 1968–1977 Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ (2012) Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 (21): 1968–1977
19.
go back to reference Richeldi L, Costabel U, Moises S, Kim DS, Hansell DM, Nicholson AG et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087PubMedCrossRef Richeldi L, Costabel U, Moises S, Kim DS, Hansell DM, Nicholson AG et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087PubMedCrossRef
20.
go back to reference Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082PubMedCrossRef Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370:2071–2082PubMedCrossRef
21.
go back to reference Collard HR, Brown KK, Martinez JJ, Raghu G, Roberts RS, Anstrom KJ (2014) Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest 146(5):1256–1262PubMedPubMedCentralCrossRef Collard HR, Brown KK, Martinez JJ, Raghu G, Roberts RS, Anstrom KJ (2014) Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest 146(5):1256–1262PubMedPubMedCentralCrossRef
22.
go back to reference Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 24(137):420–427PubMedCrossRef Harari S, Caminati A (2015) Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 24(137):420–427PubMedCrossRef
23.
go back to reference Raghu G, Weycher D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810–816PubMedCrossRef Raghu G, Weycher D, Edelsberg J, Bradford WZ, Oster G (2006) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174:810–816PubMedCrossRef
24.
go back to reference Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980–985PubMedPubMedCentralCrossRef Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980–985PubMedPubMedCentralCrossRef
25.
go back to reference Ohno S, Nakaya T, Bando M, Sugyma Y (2008) Idiopathic pulmonary fibrosis—results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 13:926–928PubMedCrossRef Ohno S, Nakaya T, Bando M, Sugyma Y (2008) Idiopathic pulmonary fibrosis—results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 13:926–928PubMedCrossRef
26.
go back to reference Navaratnam V, Fleming KM, West J, Smith CJP, Jenkins RG, Fogarty A, Hubbard RB (2011) The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 66:462–467PubMedCrossRef Navaratnam V, Fleming KM, West J, Smith CJP, Jenkins RG, Fogarty A, Hubbard RB (2011) The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 66:462–467PubMedCrossRef
27.
go back to reference Lai CC, Wang C-Y, Lu H-M, Chen L, Teng N-C, Yan Y-H et al (2012) Idiopathic pulmonary fibrosis in Taiwan—a population-based study. Respir Med 106:1566–1574PubMedCrossRef Lai CC, Wang C-Y, Lu H-M, Chen L, Teng N-C, Yan Y-H et al (2012) Idiopathic pulmonary fibrosis in Taiwan—a population-based study. Respir Med 106:1566–1574PubMedCrossRef
28.
29.
go back to reference Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR (2016) Incidence and prevalence of idiopathic pulmonary fibrosis in US adult 18–64 years old. Eur Respir J 48:179–186PubMedCrossRef Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR (2016) Incidence and prevalence of idiopathic pulmonary fibrosis in US adult 18–64 years old. Eur Respir J 48:179–186PubMedCrossRef
30.
go back to reference Tarride JE, Hopkins RB, Burke N, Guertin JR, O’Reilly D, Fell CD et al (2018) Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Clinicoecon Outcomes Res 10:127–137PubMedPubMedCentralCrossRef Tarride JE, Hopkins RB, Burke N, Guertin JR, O’Reilly D, Fell CD et al (2018) Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Clinicoecon Outcomes Res 10:127–137PubMedPubMedCentralCrossRef
31.
go back to reference Esposito DB, Lanes D, Donneyong M, Holick CN, Lasky JA, Lederer D, et al (2015) Idiopathic pulmonary fibrosis in United States Automated Claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med 192(10):1200–1207 Esposito DB, Lanes D, Donneyong M, Holick CN, Lasky JA, Lederer D, et al (2015) Idiopathic pulmonary fibrosis in United States Automated Claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med 192(10):1200–1207
32.
go back to reference Fellegi IP, Sunter AB (1969) A theory for record linkage. J Am Stat Assoc 64:1183–1210CrossRef Fellegi IP, Sunter AB (1969) A theory for record linkage. J Am Stat Assoc 64:1183–1210CrossRef
33.
go back to reference Newcombe HB (1988) Handbook of record linkage: methods for health and statistical studies, administration, and business. Oxford University Press, Incorporate Newcombe HB (1988) Handbook of record linkage: methods for health and statistical studies, administration, and business. Oxford University Press, Incorporate
34.
go back to reference Fornari C, Madotto F, Demaria M, Romanelli A, Pepe P, Raciti M et al (2008) Record-linkage procedures in epidemiology: an Italian multicentre study. Epidemiol Prev 32:79–88PubMed Fornari C, Madotto F, Demaria M, Romanelli A, Pepe P, Raciti M et al (2008) Record-linkage procedures in epidemiology: an Italian multicentre study. Epidemiol Prev 32:79–88PubMed
35.
go back to reference Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee Y-C, Collard HR (2014) Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence prevalence and survival 2001–11. Lancet Respir Med 2(7):566–572PubMedCrossRef Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee Y-C, Collard HR (2014) Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence prevalence and survival 2001–11. Lancet Respir Med 2(7):566–572PubMedCrossRef
36.
go back to reference Ley B, Urbania T, Husson G, Vittinghoff E, Brush DR, Eisner MD et al (2017) Code-based diagnostic algorithms for idiopathic pulmonary fibrosis. Case validation and improvement. Ann Am Thorac Soc 14:880–887PubMedPubMedCentralCrossRef Ley B, Urbania T, Husson G, Vittinghoff E, Brush DR, Eisner MD et al (2017) Code-based diagnostic algorithms for idiopathic pulmonary fibrosis. Case validation and improvement. Ann Am Thorac Soc 14:880–887PubMedPubMedCentralCrossRef
37.
go back to reference Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139PubMedCrossRef Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130–1139PubMedCrossRef
38.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
39.
go back to reference David S (2007) Handbook of parametric and nonparametric statistical procedures. Ed. Chapman & Hall/CRC (4th edition). David S (2007) Handbook of parametric and nonparametric statistical procedures. Ed. Chapman & Hall/CRC (4th edition).
40.
go back to reference Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691PubMedCrossRef Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–691PubMedCrossRef
41.
go back to reference Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C (2019) The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study. Eur Respir J 53(3):1801587PubMedCrossRef Torrisi SE, Ley B, Kreuter M, Wijsenbeek M, Vittinghoff E, Collard HR, Vancheri C (2019) The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicenter observational study. Eur Respir J 53(3):1801587PubMedCrossRef
42.
go back to reference Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T et al (2016) Impact of comorbidities on mortality inpatients with idiopathic pulmonary fibrosis. PLoS ONE 11(3):e0151425PubMedPubMedCentralCrossRef Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T et al (2016) Impact of comorbidities on mortality inpatients with idiopathic pulmonary fibrosis. PLoS ONE 11(3):e0151425PubMedPubMedCentralCrossRef
43.
go back to reference Mannino DM, Etzel RA, Parrish RG (1996) Pulmonary fibrosis deaths in the United States, 1979–1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 153:1548–1552PubMedCrossRef Mannino DM, Etzel RA, Parrish RG (1996) Pulmonary fibrosis deaths in the United States, 1979–1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med 153:1548–1552PubMedCrossRef
44.
go back to reference Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431–440PubMedCrossRef Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431–440PubMedCrossRef
45.
go back to reference Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J et al (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183–1188PubMedCrossRef Han MK, Murray S, Fell CD, Flaherty KR, Toews GB, Myers J et al (2008) Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 31:1183–1188PubMedCrossRef
46.
go back to reference Collard HR, Chen SY, Yeh WS, Li Q, Lee Y-C, Wang A, Raghu G (2015) Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12(7): 981–987 Collard HR, Chen SY, Yeh WS, Li Q, Lee Y-C, Wang A, Raghu G (2015) Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12(7): 981–987
47.
go back to reference Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ (2016) Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. PBM Pulm Med 16:2CrossRef Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ (2016) Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. PBM Pulm Med 16:2CrossRef
48.
go back to reference Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathicpulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37(2):356–363PubMedCrossRef Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathicpulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37(2):356–363PubMedCrossRef
49.
go back to reference Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al (2005) IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (12pt 1):963–967 Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al (2005) IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142 (12pt 1):963–967
50.
go back to reference du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A et al (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(4):459–466PubMedCrossRef du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A et al (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(4):459–466PubMedCrossRef
51.
go back to reference Brown AW, Fischer CP, Shlobin OA, Buhr RG, Shahzad Ahmad S, Weir NA, Nathan SD (2015) Outcomes after hospitalization in idiopathic pulmonary fibrosis. A cohort study. Chest 147(1):173–179PubMedCrossRef Brown AW, Fischer CP, Shlobin OA, Buhr RG, Shahzad Ahmad S, Weir NA, Nathan SD (2015) Outcomes after hospitalization in idiopathic pulmonary fibrosis. A cohort study. Chest 147(1):173–179PubMedCrossRef
52.
go back to reference Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR (2016) Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 194:711–718PubMedPubMedCentralCrossRef Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR (2016) Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 194:711–718PubMedPubMedCentralCrossRef
53.
go back to reference Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O et al (2019) Comorbidities on IPF: an underestimated issue. Eur Respir Rev 28(153):190044PubMedCrossRef Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O et al (2019) Comorbidities on IPF: an underestimated issue. Eur Respir Rev 28(153):190044PubMedCrossRef
54.
go back to reference Hyldgaard C, Hilberg O, Bendstrup E (2014) How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 108(4):647–653PubMedCrossRef Hyldgaard C, Hilberg O, Bendstrup E (2014) How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 108(4):647–653PubMedCrossRef
55.
go back to reference Caminati A, Madotto F, Cesana GC, Conti S, Harari S (2015) Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 24:436–444PubMedCrossRef Caminati A, Madotto F, Cesana GC, Conti S, Harari S (2015) Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 24:436–444PubMedCrossRef
56.
go back to reference Behr J, Wirtz H, Pittrow D et al (2014) Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: follow-up results of the INSIGHTS-IPF Registry. Eur Respir J 17(7):A600 Behr J, Wirtz H, Pittrow D et al (2014) Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: follow-up results of the INSIGHTS-IPF Registry. Eur Respir J 17(7):A600
Metadata
Title
The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities
Authors
Antonella Caminati
Fabiana Madotto
Sara Conti
Giancarlo Cesana
Lorenzo Mantovani
Sergio Harari
Publication date
01-10-2021
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 7/2021
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-021-02651-w

Other articles of this Issue 7/2021

Internal and Emergency Medicine 7/2021 Go to the issue

CE - MEDICAL ILLUSTRATION

Incysting transformation

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine